PAMVAC VLP
Alternative Names: PAMVAC-VLPLatest Information Update: 28 Feb 2023
At a glance
- Originator AdaptVac
- Class Protozoan vaccines; Subunit vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malaria
Most Recent Events
- 30 Jan 2023 Preclinical trials in Malaria (Prevention) in Denmark (Parenteral) (AdaptVac pipeline; January 2023)
- 30 Jan 2023 PAMVAC VLP plans a phase-I trial for Malaria (Prevention) in 2025 (Parenteral) (AdaptVac pipeline; January 2023)
- 30 Jan 2023 PAMVAC VLP plans a phase-II trial for Malaria (Prevention) in 2026 (Parenteral) (AdaptVac pipeline; January 2023)